Atazanavir (Reyataz®)

Following a full submission.

Atazanavir (Reyataz) is accepted for restricted use within NHS Scotland for the treatment of HIV-1 infected, antiretroviral treatment experienced adults, in combination with other antiretroviral medicinal products in those patients who do not require concomitant statin use.

The combination of atazanavir and ritonavir was non-inferior to a standard boosted protease inhibitor (PI) regimen in patients with moderate previous exposure to PIs, however, it was inferior in patients with PI-resistant viruses. It was associated with lower incidences of diarrhoea and lipid adverse-effects and a higher incidence of hyperbilirubinaemia.

The health economic case for use is acceptable when atazanavir is compared with a standard boosted protease inhibitor regime in patients receiving concomitant statins.